Table 4– Adverse events occurring in ≥10% of macitentan-treated subjects
Macitentan 10 mgPlacebo
Subjects11959
Worsening of IPF25 (21.0)15 (25.4)
Dyspnoea24 (20.2)9 (15.3)
Cough22 (18.5)22 (35.6)
Upper respiratory tract infection20 (16.8)12 (20.3)
Bronchitis16 (13.4)9 (15.3)
Peripheral oedema14 (11.8)4 (6.8)
Anaemia13 (10.9)0 (0.0)

  • Data are presented as n or n (%). Data are from subjects in the all-randomised set. IPF: idiopathic pulmonary fibrosis.